China
Africa
Explore chapters and articles related to this topic
Soybean-Based Functional Foods Through Microbial Fermentation: Processing and Biological Activities
Published in Megh R. Goyal, Arijit Nath, Rasul Hafiz Ansar Suleria, Plant-Based Functional Foods and Phytochemicals, 2021
Arijit Nath, Titas Ghosh, Abinit Saha, Klára Pásztorné Huszár, Szilvia Bánvölgyi, Renáta Gerencsérné Berta, Ildikó Galambos, Edit Márki, Gyula Vatai, Andras Koris, Arpita Das
Bowman-Birk inhibitor suppresses reactive-oxygen-species induced mitochondrial damage after proteasomal inhibition and angiogenesis [19, 64, 99], Amino acid sequence in lunasin peptide is almost similar to Bowman-Birk inhibitor. Structurally, lunasin is 43 amino acid having nine aspartic acid residues at the C-terminal end with a cell adhesion motif preceding to it. Tri-peptide RGD (Arg-Gly-Asp) from the sequence helps its binding with the non-acetylated H3 and H4 histones to prevent their acetylation and anti-carcinogenic activity [65, 84]. It has been reported that Bowman-Birk inhibitor has a role in the protection of lunasin from gastrointestinal degradation [12, 85].
Synthesis of Bioactive Peptides for Pharmaceutical Applications
Published in Peter Grunwald, Pharmaceutical Biocatalysis, 2019
Jaison Jeevanandam, Ashish Kumar Solanki, Shailza Sharma, Prabir Kumar Kulabhusan, Sapna Pahil, Michael K. Danquah
Amongst several sources, bioactive peptides of plant origin have attracted much attention. Proteins (lectins) and proteases (cystatin, serpin, and lunasin) from plants have been studied for their potential as anti-cancer agents and the studies revealed that lunasin exhibits side effects of anti-neoplasm towards breast, prostate, skin, leukemia and lymphoma cell lines with diverse mechanisms (Hernandez-Ledesma and Hsieh, 2017). Phyto-peptides, namely lunasin, are found in seeds, legumes, and mainly soya beans; in a recent study, these peptides in the fractions of <5, 5–10, and 10–50 kDa were obtained from soybeans seeds. This study demonstrated the excellent anticancer potential of these phyto-peptides against breast (MCF-7), blood (CCRF-CEM and Kasumi-3), and prostate (PC-3) cancer cell lines. The peptide fractions showed 68.0% inhibition in the cancer cell lines, while the minimum inhibitory concentration (IC50) ranged between 608 and 6786 μg/mL. This peptide was proposed to be useful in alternative cancer therapy, as either nutritional supplements or food products (Rayaprolu et al., 2017). In another study, egg yolk peptides were prepared from the byproducts of egg yolk protein, after lecithin extraction and purification. The filtrated fraction (EYGF-33) significantly inhibited growth of colon cancer cells (Caco-2) without any adverse reactions in normal human epithelial colon cells (HCEC). This significant activity was observed due to the enhanced production of superoxide ions in mitochondria, which is supported by the externalization of phosphatidyl serine (Yousr et al., 2017).
Nutritional Attributes of Cereal Grains And Legumes as Functional Food: A Review
Published in Megh R. Goyal, Durgesh Nandini Chauhan, Plant- and Marine-Based Phytochemicals for Human Health, 2018
Vikas Dadwal, Himani Agrawal, Shriya Bhatt, Robin Joshi, Mahesh Gupta
Lunasin peptide containing 43 amino acids was initially found in soybean and then also identified in some pseudo cereals and cereals for instance, rice, barley, wheat, rye, and amaranth.64−66, 115 Bioactivity of the lunasin is related to its capability to arrest cell division in cancer cells, to inhibit core histone acetylation in mammalian cells, and to protect DNA from oxidative damage.59 Bioactive peptides from legumes and cereals possess a number of physiological effects in vitro as well as in animal models. Peptide potential should not be shocking. All intercellular communications and cellular functions of the body are directed by amino acid sequences present in peptides or in protein. Proteins and peptides acquire a variety of chemical diversities, which is not offered by any other biological molecule. They are tool kits of the nature; and the more we can use native peptides or closely related analogs in order to protect health, the more we could decrease the risk of unforeseen side reactions.
The Effect of Soybean Lunasin on Cardiometabolic Risk Factors: A Randomized Clinical Trial
Published in Journal of Dietary Supplements, 2020
Sara Haddad Tabrizi, Ella Haddad, Sujatha Rajaram, Keiji Oda, Amandeep Kaur, Joan Sabaté
Lunasin is a unique 43–amino acid peptide encoded by the soy Gm2S-1 gene (Odani et al. 1987; Galvez and de Lumen 1999). Its C-terminal end has nine aspartic acid residues and an arginine-glycine-aspartic acid cell adhesion motif. The helix spanning glutamic acid 23 to isoleucine 30 has a structure homologous to chromatin-binding protein (Galvez et al. 2001). Initial studies of its biological activity in various mammalian cell lines found that lunasin blocked cell division by binding to specific chromosomal histones, leading to mitotic arrest and cell death (de Lumen 2008; Jeong et al. 2007). Lunasin has been demonstrated to have anticancer properties mediated through the inhibition of the acetylation of histones H3 and H4 (de Mejia et al. 2010). Further investigation has shown that lunasin may also regulate cholesterol levels. In studies with HepG2 liver cells, the addition of lunasin resulted in down-regulation of HMG-CoA reductase expression by inhibiting acetylation of H3-lysine (Lule et al. 2015). Another study on HepG2 cells showed that expression of low-density lipoprotein receptors is upregulated by lunasin via activation of sterol regulatory element-binding protein 2 (SREBP-2), which enhances LDL uptake in HepG2 cells (Gu et al. 2017).
Lunasin abrogates the expression of matrix metalloproteinases and reduction of type II collagen
Published in Artificial Cells, Nanomedicine, and Biotechnology, 2019
Weihua Dai, Zhiyong Liang, Hongbo Liu, Guangzong Zhao, Chunfang Ju
Lunasin, a well-known natural peptide, was found in the soybean [7]. It has displayed positive impacts on numerous physiological functions in living beings. Increasing evidence shows that lunasin has protective properties that are effective in the treatment of various diseases, including neurodegenerative diseases, heart disease and bone disorders [8]. Patents taking lunasin have demonstrated that this peptide exhibits a diverse range of biological activities, which include anti-inflammatory, anti-diabetes and anti-cancer properties [9]. Due to these beneficial roles, numerous nutritional supplements containing lunasin are offered. It has been identified that daily dietary supplementation with 125 mg lunasin exerts protective effects in terms of heart health and cholesterol management. Additionally, a kind of lunasin extract from Mexico has been successfully applied for developing soy beverages and functional foods [10]. The anti-inflammatory function of lunasin has been studied in recent investigations. Significantly, lunasin could inhibit the secretion of IL-1β [11]. However, the pharmacological role of lunasin in OA has not been known. Here, we report that lunasin treatment prevented IL-1β-mediated loss of type II collagen by inhibiting MMP-3 and MMP-13.
Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial
Published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019
R.S. Bedlack, Paul Wicks, Timothy Vaughan, Alicia Opie, Rebecca Blum, Amanda Dios, Ghazaleh Sadri-Vakili
Lunasin is a peptide first isolated from soybeans (1). It is reported to alter histone acetylation patterns (2–5) which are abnormal in PALS (6), may contribute to epigenetic transcriptional and translational dysregulation (7) and have been the target of previous (6,8) and ongoing (NCT03127514) clinical trials. In 2014 a US television news story reported that a person diagnosed with ALS experienced a dramatic improvement in his speech, swallowing, and limb strength while on a Lunasin regimen (9). As part of an ALSUntangled report, this person’s lower-motor-neuron-predominant ALS (sometimes called progressive muscular atrophy) and improvements were independently validated (10). In our review of the available literature, Lunasin was generally regarded as safe, with no previously known serious adverse effects (10). Based on this and a high level of interest from patients, we decided to perform a pilot trial of Lunasin in people with ALS (PALS).